Defunding the DEA with Joe Moore of Psychedelics Today
Similar Posts
Meet MindMed’s Interim CEO: Robert Barrow | My First Impressions & Comments
MindMed’s Interim CEO, Robert Barrow, has not made as many public appearances as opposed to MMED’s previous CEO, Jr Rahn.
As many of you know, almost two months ago, then MindMed’s CEO, JR Rahn, announced that he was stepping down, and he would be replaced immediately by Robert Barrow, then Chief Development Officer.
Since then, we have not had a lot of news from the company, and though we have heard from Barrow on previous Conference Calls, us the retail investors, have not had a chance to meet the man (at least digitally) as CEO yet.
That changed on August 3rd, when MNMD held a “fireside chat” over Zoom with Barrow, where we got to know him a little better, and he provided us with some new information.
In this video, we will play the most important clips and offer some commentary where necessary.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedStock #MNMD
Atai Life Sciences IPOing TOMORROW ( Is Atai a BUY?)
ATAI IPOS TOMORROW! It’s finally happening! This Friday, on June 18th, 2021, the company I’ve been talking about for a while now, Atai Life Sciences, is set to IPO on the NASDAQ stock exchange, under ticker symbol “atai”.
This will automatically make Atai a runner for the title of the most advanced public psychedelic medicines company on the market.
So in this episode, we’ll discuss several things:
1. The details of the IPO
2. We’ll take a look at their financials
3. Look at Atai Life Sciences’ investment thesis
4. What I will be doing
Enjoy the episode!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Website: https://thepsychedelicinvestor.com/
editing: @themyaholy
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
https://www.atai.life/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Atai #AtaiLifeSciences #AtaiIPO
MindMed (MMED) Cluster Headaches LSD Trials Update (and response to criticisms)
Hey guys! Here is an Update and response to our easily most controversial video “MindMed (MMED) Suicide Headaches trial VANISHES from Website ( What Happened?)”. We got a response from MindMed while also receiving some backlash from the MindMed investors community that will be addressed. Hope you guys find some value in this video. I appreciate you guys. LOOVE all comments and criticisms. Caio!
P.S. S/O to Magic Shrooms who also contributed by commenting that he “received a reply from MMED concerning about the cluster headaches trial. they said that there has been no changes in regard to their on-going trial using LSD for suicide headaches!”
Just to let you know, we temporarily (perhaps permanently?) have removed the first video, while we discuss how to move forward.
Subscribe to our channel to get the latest updates on Psychedelic Stocks. Follow the MMED stock and other companies like it.
Let us know in the comments what you think about the new way we edited our video? Do you like it more than how we edited them previously?
🎵 Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #mmed #mindmedstock #psychedelicstocks #mmedf
Music as Medicine – Music’s Role in Mental Health & Psychedelic Therapy | Payton Nyquvest
In this segment of Spotlight In Focus, Psychedelic Spotlight’s Matthew…
Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!
Compass Pathways is launching a NEW Phase II clinical trial to treat PTSD!!!
The trial will use Comp 360, the company’s synthetic, proprietary version of psilocybin, in conjunction with therapy. This is Compass’ second major trial using Comp 360. They also are using it to treat Treatment Resistant Depression.
On October 3rd, 2021, Compass Pathways (Nasdaq: CMPS) announced the launch of a brand new psychedelic therapy clinical trial, using Psilocybin, the active ingredient in magic mushrooms, to treat PTSD.
The Phase 2 clinical trial will use Comp 360, Compass Pathways’ proprietary, synthetic, cristalline Psilocybin. It will be paired with talk psychotherapy in 20 adults who suffered trauma as an adult, resulting in PTSD.
While using psychedelics for mental health may seem controversial, when it comes to the science, psychedelics like psilocybin and MDMA, when paired with therapy have been shown to work.
For example, recently MAPS completed a Phase III clinical trial using MDMA therapy to treat PTSD, which showed 67% of people improving so much they no longer qualified to be diagnosed as having PTSD (cured?). Another 21% of people improved significantly.
This Compass Pathways trial is exciting, because once it is complete, we will be able to compare the results of their psilocybin trial to MAPS’ MDMA trial, to start to have an understanding of which psychedelic compound works better for treating PTSD.
This news comes as we are waiting for the results of Compass Pathways’ Phase 2b Clinical Trial, testing treating Treatment-Resistant Depression with Comp 360, to be released before the end of the year.
The results of the trial will be significant, as it will be the largest ever clinical trial studying psychedelics, with 216 patients. It will also be the most advanced clinical trial studying psilocybin, being in phase 2b.
In sum, these are very exciting times to be watching Compass Pathways. Controversies surrounding their patents aside, Compass is one of the companies pushing the frontiers of psychedelic medicines, which is very exciting to watch.
Do you think psilocybin assisted therapy could treat PTSD? Let us know in the comments.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #Psychedelics #CMPS